Both TYROBP deficiency and C3 deficiency, as well as the TLR5 and Nurr1 expression patterns, need to be further explored to see how they protect or prevent dysregulation of these above-mentioned pathways and to select the most promising multi-target drug candidate to encounter AD pathology. Here, NR4A2 is linked to Alzheimer disease.